LIXTE Biotechnology Holdings, Inc. announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin. Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 USD | +3.93% | -12.50% | +1.28% |
May. 09 | Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | Lixte Biotechnology Files Up to $50 Million Mixed Shelf | MT |
1st Jan change | Capi. | |
---|---|---|
+1.28% | 5.35M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+48.54% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol